Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)-Reference-Cited by-同舟云学术

Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)

Published:2024-05-26 Issue:1 Volume:35 Page:
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Pinter Andreas¹,Eyerich Kilian²³,Costanzo Antonio⁴⁵,Garrelts Alyssa⁶,Schuster Christopher⁶⁷,Mert Can⁸,Lampropoulou Anastasia⁶,Fotiou Konstantinos⁶,Maul Julia-Tatjana⁹¹⁰,Papp Kim A.¹¹¹²^ORCID

Affiliation:

1. Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Frankfurt am Main, Germany

2. Department of Dermatology and Venerology, Medical Center, University of Freiburg, Freiburg im Breisgau, Germany

3. Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

4. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy

5. Dermatology, Humanitas Research Hospital IRCCS, Rozzano, Milan, Italy

6. Eli Lilly and Company, Indianapolis, Indiana, USA

7. Department of Dermatology, Medical University of Vienna, Vienna, Austria

8. HaaPACS GmbH, Schriesheim, Germany

9. Department of Dermatology, University Hospital Zurich, Zurich, Switzerland

10. Faculty of Medicine, University of Zürich, Zurich, Switzerland

11. Alliance Clinical Trials and Probity Medical Research, Waterloo, Ontario, Canada

12. Division of Dermatology, Department of Medicine, University of Toronto, Ontario, Canada

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2024.2350227

Reference17 articles.

1. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes ( PSoHO )

2. A 24‐week multicentre, randomized, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate‐to‐severe plaque psoriasis naive to systemic treatment

3. Comparison of physical and mental functioning among moderate-to-severe psoriasis patients on biologic versus oral therapy

4. The journey of adult psoriasis patients towards biologics: past and present - Results from the BioCAPTURE registry

5. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate‐to‐severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO‐BIO‐REAL)